Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor

Pharmacogenetics and Genomics

Volumn 17, Issue 5, 2007, Pages 359-368

  Costa Scharplatz, Madlaina ^a,e   Van Asselt, Antoinette D I ^c   Bachmann, Lucas M ^a,b   Kessels, Alfons G H ^c   Severens, Johan L ^c,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ACE I D polymorphism; Angiotensin converting enzyme inhibitor; Cost effectiveness; Pharmacogenetic testing; Pharmaeconomics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ACUTE KIDNEY FAILURE; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG SUBSTITUTION; ECONOMIC EVALUATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PREDICTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; RENAL DIALYSIS;

EID: 34247256637     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000236336.34175.e8     Document Type: Article

References (29)

1. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87.
2. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110:724-731.
3. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252-1256.
4. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian study group of the effects of enalapril treatment in proteinuric renal disease156. Kidney blood Press Res 1998; 21:66-69.
5. Rigat B, Hubert C, Alhencgelas F, Cambien F, Corvol P, Soubrier F. An insertion deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
6. Navis G, Van Der Kleij FGH, de Zeeuw D, de Jong PE. Angiotensinconverting enzyme gene I/D polymorphism and renal disease. J Mol Med 1999; 77:781-791.
7. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM. Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. Curr Control Trials Cardiovasc Med 2005; 6:16.
8. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000; 57:274-281.
9. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6:217-227.
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-338.
11. Pedersen OD, Gram J, Jeunemaitre X, Billaud E, Jespersen J. Does longterm angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Coron Artery Dis 1997; 8:283-291.
12. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 2000; 11: 88-96.
13. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices: modeling studies. Value Health 2003; 6:9-17.
14. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes [see comment] [Review] [43 refs]. N Engl J Med 2002; 346:1145-1151.
15. Working Party of the International Diabetes Federation (European Region). Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines [Review] [109 refs]. Diabet Med 2003; 20:972-987.
16. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: The CHARM-Alternative Trial. Lancet 2003; 362:772-776.
17. Sica DA. ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congest Heart Fail 2004; 10:160-164.
18. Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889-897.
19. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus 97. Q J Med 2001; 94:89-94.
20. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. EURODIAB controlled trial of lisinopril in IDDM. Diabetes 1998; 47: 1507-1511.
21. USRDS Report 2004. Available at: http://www.usrds.org/adr.htm [Accessed in June 2006].
22. Valderrabano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 (Suppl 5):1-25.
23. Schadlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001; 19: 497-512.
24. Oostenbrink JDKM, Rutten FFH. Manual for costing: methods and standard costs for economic evaluation in health care [in Dutch]. Coll Zorgverzekeringen; 2000. p. 45.
25. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004; 7:397-401.
26. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005; 8:1-2.
27. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005; 7:495-500.
28. Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy- betamethylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004; 14:53-60.
29. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001; 59:286-294.